Drugs / agenT-797
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05108623 | Jan 2022 → Jan 2024 | — | MiNK Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04754100 | Mar 2021 → Jan 2023 | refractory plasma cell neoplasm | MiNK Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04582201 | Sep 2020 → Apr 2023 | adult acute respiratory distress syndrome | MiNK Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07550088 | Jun 2026 → Sep 2028 expected | colorectal cancer | Scripps Health | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07615010 | May 2026 → Jun 2027 expected | pneumonia | MiNK Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT07492888 | Apr → Nov 2026 | adult acute respiratory distress syndrome, infectious disease with sepsis, lymphopenia, pneumonia | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06251973 | Feb 2024 → Aug 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07492875 Comparator | Apr 2026 → Apr 2029 | acute respiratory distress syndrome, immunodeficiency disease, infectious disease with sepsis, lymphopenia +1 | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AgenT-797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07492888 ↗ |
| Modality | Cell therapy | “agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.” NCT04582201 ↗ |
| Route | Intravenous | “agenT-797 will be administered to hospitalized participants as a single intravenous infusion.” NCT04582201 ↗ |